Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Donepezil
Treatment for Alzheimer's Disease
Typical Dosage: 5-10 mg orally once daily
Effectiveness
45%
Safety Score
60%
Clinical Trials
202
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg orally once daily
Time to Effect
4-6 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$400
Side Effect Mgmt:$50
Total Annual:$525
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.05
Outcome-Based Costs
Cost per Responder
$2,100
Donepezil Outcomes
for Alzheimer's Disease
Efficacy Outcomes
Overall Effectiveness
+45%
Response Rate
+25%
Common Side Effects
Nausea
+11%
Diarrhea
+9%
Insomnia
+9%
Muscle cramps
+8%
Vomiting
+6%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Donepezil in Alzheimer's Disease
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
NCT01245530COMPLETEDPHASE3
280 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jun 1, 2008
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
NCT01266525COMPLETEDPHASE2
291 participants
INTERVENTIONAL
Gilbert, United States +81 more
Started: Feb 1, 2011
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
NCT02097056COMPLETEDPHASE4
171 participants
INTERVENTIONAL
Ansan, South Korea +12 more
Started: Feb 1, 2014
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
NCT02064920COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Started: Apr 22, 2014
Neural Correlates In Mild Alzheimer's Disease
NCT00477659COMPLETEDPHASE4
14 participants
INTERVENTIONAL
Milwaukee, United States
Started: Jul 23, 2007
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
NCT01539031COMPLETEDPHASE3
351 participants
INTERVENTIONAL
Anjo, Japan +53 more
Started: Mar 1, 2012
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
NCT02787746COMPLETEDPHASE4
241 participants
INTERVENTIONAL
Beijing, China
Started: Apr 1, 2016
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
NCT02550665COMPLETEDPHASE3
176 participants
INTERVENTIONAL
Seoul, South Korea
Started: Dec 1, 2014
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
NCT00566501COMPLETEDPHASE3
915 participants
INTERVENTIONAL
Santa Ana, United States
Started: Dec 14, 2007
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
NCT00478205COMPLETEDPHASE3
1.47K participants
INTERVENTIONAL
Hickory, United States
Started: Jun 1, 2007
A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
NCT03259958COMPLETEDPHASE1
86 participants
INTERVENTIONAL
Phoenix, United States
Started: Oct 30, 2017
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
NCT01251718COMPLETED
894 participants
OBSERVATIONAL
Anjo, Japan +105 more
Started: Dec 1, 2010
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
NCT01276353COMPLETEDPHASE2
45 participants
INTERVENTIONAL
Akita, Japan +10 more
Started: Jan 1, 2011
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
NCT02158910COMPLETED
2.23K participants
OBSERVATIONAL
Busan, South Korea +12 more
Started: Mar 1, 2015
Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease
NCT00408525COMPLETEDPHASE1
41 participants
INTERVENTIONAL
Nashville, United States
Started: Dec 1, 2006
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
NCT02162264COMPLETED
8.66K participants
OBSERVATIONAL
Multiple Locations, Japan
Started: Jun 1, 2013
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
NCT00381381COMPLETEDPHASE4
199 participants
INTERVENTIONAL
Bundang, South Korea +14 more
Started: May 31, 2006
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
NCT01023867COMPLETEDNA
88 participants
INTERVENTIONAL
Seoul, South Korea
Started: Mar 1, 2007
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
NCT00230568COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Phoenix, United States +34 more
Started: Dec 1, 2005
Showing 20 of 203 total trials